Sign In
Buy ROG
$148.00
-6.22 (-4.03%)
At Close: Jun 03, 2026
Is FlexShares International Quality Dividend ETF (IQDF) a Strong ETF Right Now?
10:20am, Thursday, 21'st Jul 2022 Zacks Investment Research
Smart Beta ETF report for IQDF
Roche backs 2022 outlook as profit climbs, boosted by diagnostics sales
06:35am, Thursday, 21'st Jul 2022 MarketWatch
Roche Holding AG said Thursday that profit for the first half of the year increased as sales grew, mainly driven by the diagnostics division.
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche: Wechsel im VR-Präsidium und in der Konzernleitung im Frühling 2023
05:03am, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Basel, 21. Juli 2022 - Christoph Franz wurde 2011 in den Verwaltungsrat von Roche gewählt und präsidiert dieses Gremium seit 2014. Christoph Franz: «Ich habe mich entschieden, im kommenden Jahr nac
[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Board of Directors and Corporate Executive Committee in Spring 2023
05:03am, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Basel, 21 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Christoph Franz has decided not to seek re-election to the Board of Directors at the AGM in March 2023. The Board of Direc
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche mit guten Halbjahresergebnissen
05:00am, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Basel, 21. Juli 2022
[Annonce événementielle au sens de l’art. 53 RC] Roche enregistre de bons résultats au premier semestre 2022
05:00am, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Bâle, le 21 juillet 2022
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
05:00am, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Basel, 21 July 2022
Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease
05:00am, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
Basel, 19 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® Amyloid Plasma Pa
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
05:00am, Monday, 18'th Jul 2022 GlobeNewswire Inc.
Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available im
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
04:30pm, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
Basel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today
New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration
12:45pm, Thursday, 14'th Jul 2022 GlobeNewswire Inc.
Basel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo®
Should You Invest in the Invesco S&P SmallCap Information Technology ETF (PSCT)?
10:20am, Tuesday, 12'th Jul 2022 Zacks Investment Research
Sector ETF report for PSCT
New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A
09:45am, Monday, 11'th Jul 2022 GlobeNewswire Inc.
Basel, 11 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the primary analysis of the phase III HAVEN 6 study, which show that Hemlibra® (emicizumab) continued to demonstr
FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
05:00am, Wednesday, 06'th Jul 2022 GlobeNewswire Inc.
Basel, 6 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Pr
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
10:20am, Monday, 04'th Jul 2022 Zacks Investment Research
Style Box ETF report for IJT
